MEDIVIR, INTERIM REPORT, 1 January – 30 September 2005

• A phase IIa study on MIV-210 against multiresistant HIV began in September. • A Candidate drug (CD) was designated on the Cathepsin K project against osteoporosis in May. • BI (Boehringer Ingelheim) concluded its research collaboration with Medivir on the HIV compound MIV-310 (polymerase inhibitor) in March. Medivir has decided to prioritize its protease projects, and accordingly, will not assign in-house resources to MIV-310 until further notice. • Consolidated net sales were SEK 41.0 (18.4) m in the period. • The loss after tax was SEK -112.6 (-132.3) m; earnings per share were SEK -8.72 (-12.31). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Financial Statement will be published on 16 February 2006 The Three-month Interim Report will be published on 26 April 2006 The Annual General Meeting will be on 26 April 2006, from 3 p.m. Medivir’s financial reports are available from its Website, www.medivir.se from these dates.

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe

Documents & Links